Marizyme Aktie
WKN DE: A2JRNL / ISIN: US5703721028
01.04.2025 14:53:59
|
Qualigen Therapeutics Signs MoU To Acquire Marizyme, Stock Down In Pre-Market
(RTTNews) - Qualigen Therapeutics, Inc. (QLGN), Tuesday announced a Memorandum of Understanding to acquire Marizyme (MRZM). The financial details of the deal have not been disclosed.
The company expects the acquisition to result in rapid revenue growth beginning in 2025. Additionally, the deal would leverage Marizyme's FDA cleared DuraGraft medical device, which would help in its commercialization.
In the pre-market hours, Qualigen's stock is falling 7.42 percent to $3.37 on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ritter Pharmaceuticals Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Ritter Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Marizyme Inc Registered Shs | 0,00 | 0,00% |
|
Letzte Top-Ranking Nachrichten
Börse aktuell - Live Ticker
Erneut Gewinne an Asiens BörsenAn den Börsen in Asien geht es am Donnerstag freundlich zu.